Number of shares and voting rights of Innate Pharma as of February 1, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...Innate Pharma to participate in the 10th annual SVB Leerink Global Healthcare Conference
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the...Innate Pharma advances lacutamab clinical development program
TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated Company to initiate two new clinical trials to investigate lacutamab...Innate Pharma to host key opinion leader discussion on the potential role of lacutamab across T-cell lymphomas
Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today...Innate's first NK cell engager selected by Sanofi as drug candidate for development
IPH6101/SAR443579 is an NKp46-based NK cell engager (NKCE) that uses Innate’s proprietary multispecific antibody format Selection of IPH6101/SAR443579 triggers a €7M milestone payment to Innate Innate...Innate Pharma to participate in upcoming investor conferences
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the...Innate Pharma to return US and EU Lumoxiti commercialization rights to AstraZeneca
Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio Companies will develop a transition plan with the goal of returning...Innate Pharma to present additional efficacy data for monalizumab in combination with cetuximab in head and neck cancer at the ESMO immuno-oncology virtual congress
Phase 2 expansion cohort data supports ongoing Phase 3 trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will present...Innate Pharma 2021 financial calendar
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today released its 2021 financial calendar: March 18, 2021: Publication of 2020 financial...Innate Pharma reports third quarter 2020 financial results and business update
Lacutamab granted PRIME designation in Sézary Syndrome by the European Medicines Agency Monalizumab Phase 3 study initiated, triggering $50 million milestone payment Cash position of €163.6 million*...
